In the study cohort, 2,310 patients died during a median follow-up of 6.3 years, and prostate cancer accounted for 454 (19.7% ...

A short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of disease progression or death in patients with metachronous oligometastatic ...

In February, the company reacquired full rights to the shot from Astellas, which paid $10 million ... GSK's existing scientific footprint in the Boston area," said GSK's R&D chief Hal Barron.

Leaders of three of these companies – Philadelphia’s Interius BioTherapeutics, Seattle’s Umoja BioPharma, and Boston’s Kelonia ... has partnered with Astellas in a similar fashion.

Currently, there is no standard treatment for these patients,” says Ian Krop, an oncologist at the Dana–Farber Cancer Institute in Boston, USA, and lead investigator of the TDM4374g trial.

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance accuracy, reproducibility, and efficiency in cell manufacturing. Astellas ...

NORTHBROOK, Ill., Feb. 27, 2025 /PRNewswire/ -- Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas"), and MBC BioLabs, a premier launchpad for ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...

"As a multinational pharmaceutical company, Astellas has benefited from these supportive policies in its business growth in China, and we remain confident in the country's continuous endeavors to ...

Boston Globe CEO Linda Pizzuti Henry is backing out as an investor in Boston Unity Soccer Partners — and the new pro women’s soccer team it’s vying to bring to White Stadium — amid ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a price target of Yen1,700.00. The company’s shares ...